potassium voltage-gated channel modifier subfamily G member 1Genealiases: K13 · KCNG · KV6.1 · kH2
Q-omics provides the consensus-scored KCNG1 profile across patient tissues and cancer cell-line models. KCNG1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCNG1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, KCNG1 RNA expression shows 13,527 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where KCNG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNG1 survival associations across molecular data types. KCNG1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNG1 RNA expression–survival associations across cancer types. High KCNG1 expression shows unfavorable associations in KIRP, KIRC, ACC, HNSC, UCS and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCNG1 RNA expression.
This table summarizes KCNG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KCNG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNG1 shows lower tumor expression in COAD and UCEC and higher tumor expression in BLCA, LUSC, LUAD and CHOL. The COAD box plot shows higher KCNG1 RNA expression in normal versus tumor tissue (log2 FC = −1.309, t-test p < 0.001).
This table shows molecular features associated with KCNG1 in patient tissues and cancer cell lines. In patient samples, KCNG1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
